Necroptosis in Pulmonary Diseases: A New Therapeutic Target

Lingling Wang†, Ling Zhou†, Yuhao Zhou, Lu Liu, Weiling Jiang, Huojun Zhang* and Huiguo Liu*

Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

In the past decades, apoptosis has been the most well-studied regulated cell death (RCD) that has essential functions in tissue homeostasis throughout life. However, a novel form of RCD called necroptosis, which requires receptor-interacting protein kinase-3 (RIPK3) and mixed-lineage kinase domain-like pseudokinase (MLKL), has recently been receiving increasing scientific attention. The phosphorylation of RIPK3 enables the recruitment and phosphorylation of MLKL, which oligomerizes and translocates to the plasma membranes, ultimately leading to plasma membrane rupture and cell death. Although apoptosis elicits no inflammatory responses, necroptosis triggers inflammation or causes an innate immune response to protect the body through the release of damage-associated molecular patterns (DAMPs). Increasing evidence now suggests that necroptosis is implicated in the pathogenesis of several human diseases such as systemic inflammation, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, neurological diseases, and cancer. This review summarizes the emerging insights of necroptosis and its contribution toward the pathogenesis of lung diseases.

Keywords: necroptosis, ripk1, ripk3, mlkl, pulmonary diseases

INTRODUCTION

The normal growth and development of multicellular organisms depend on the balance between cell death, which clears damaged, infected, or redundant cells, and cell proliferation (Galluzzi et al., 2018). Two modalities of cell death have been classically recognized: one is accidental cell death caused by a sudden and intolerable physical, chemical, or mechanical factor, including necrosis, and the other is RCD via genetically encoded mechanisms, widely known as apoptosis (Degterev et al., 2005). RCD can occur in the absence of external stimuli, including organ development or tissue replacement, and is often referred to as programmed cell death. In addition, it can occur in cells that cannot adapt to the intracellular and extracellular microenvironments disturbed by stressors. Apoptosis is a prototypical form of RCD, characterized by cell membrane sclerosis, nuclear chromatin concentration, nuclear fragmentation, and plasma membrane bubbling. Necroptosis, termed so in 2005, is a regulated form of cell death that shares an upstream signaling pathway with apoptosis, and the underlying molecular mechanisms of the two processes considerably overlap (Linkermann and Green, 2014; Vanden Berghe et al., 2016). However, the death morphology of necroptosis is similar to necrosis, but not apoptosis, and is characterized by cell membrane hardening, nuclear chromatin concentration, nuclear fragmentation, and plasma membrane bubbling (Galluzzi et al., 2018).

Necroptosis also plays an important role in the early developmental stages (Lin et al., 2016; Shan et al., 2018), and is a defense mechanism against infectious diseases (Li et al., 2012; Wang X. et al., 2016).
| Disease | More specific | Main content about necroptosis | References |
|---------|--------------|--------------------------------|------------|
| **Infection** | S. aureus pneumonia | The accessory gene regulator (agr) quorum sensing system can be inhibited by the heptapeptide RNAIII-inhibiting peptide, which dampens (Phenol-soluble modulins) PSMA-induced neutrophil necroptosis | Zhou et al. (2018) |
| | | S. aureus activates the NLRC4 to suppress γδ T cell-derived IL-17A-dependent neutrophil recruitment by driving necroptosis and IL-18 production, which impedes host defense | Paudel et al. (2019) |
| | | NLRP6 expression is increased, triggering necroptosis and hyper-inflammation via the TNF-α pathway, leading to the loss of neutrophils by dampening IFN-γ and ROS production | Ghimire et al. (2018) |
| | | Agr-regulated toxins activate necroptosis and IL-1β expression, leading to alveolar macrophage depletion and lung injury | Kitur et al. (2015) |
| **Bacterial PFTs** | PFTs-induced respiratory epithelial cell RIP1/RIP3/MLKL-dependent necroptosis, as a result of influenza-induced oxidative stress, was triggered by ion dysregulation through PFT-mediated membrane permeabilization | Gonzalez-Juarbe et al. (2017), Gonzalez-Juarbe et al. (2020) |
| | PFTs induce necroptosis of macrophages through ion dysregulation, mitochondrial damage, ATP depletion, and oxidative stress | Gonzalez-Juarbe et al. (2015) |
| Klebsiella pneumoniae (KPh) | TNFa excess triggers ROS production then induces RIPK1-RIPK3-dependent necroptosis of macrophages, leading to bacterial dissemination | Roca and Ramakrishnan (2013) |
| | TNFa excess leads to RIPK1-RIPK3-dependent necroptosis in murine fibroblasts and RIPK1-dependent necrosis-like cell death in murine macrophages | Butler et al. (2017) |
| | Virulent Mtb evasion of macrophages apoptosis and immunity by Bcl-xL, inducing RIPK3–impedent necrosis and preventing caspase 8-activation | Zhao et al. (2017) |
| | The inhibition of necroptosis by MLKL-deficiency or Nec-1 in humanized mice does not affect Mtb infection progression | Stutz et al. (2018a) |
| | RIPK3 is not an important mediator of pathological inflammation or macrophage necrosis in Mtb, for the reason is that inhibition of RIPK3 is not effective | Stutz et al. (2018b) |
| **Influenza virus** | RIPK3 is activated by IAV and plays a crucial role in antiviral immunity by activating MLKL-dependent necroptosis with RIPK3 kinase activity and FADD-mediated apoptosis. ZBP1 is the link between IAV and RIPK3 activation, and ZBP1 deficiency is resistant to IAV-triggered necroptosis and apoptosis | Downey et al. (2017) |
| | RIPK3 is activated by IAV and plays a crucial role in antiviral immunity by activating MLKL-dependent necroptosis with RIPK3 kinase activity and FADD-mediated apoptosis. ZBP1 is the link between IAV and RIPK3 activation, and ZBP1 deficiency is resistant to IAV-triggered necroptosis and apoptosis | Nogusa et al. (2016), Thapa et al. (2016) |
| | Z-RNAs generated by replicating IAV activate ZBP1, activating RIPK3 and MLKL, thus leading to nuclear membrane rupture and resulting in a nucleus-to-cytoplasm necroptosis. In unrestrained cell death, MLKL-induced nuclear rupture causes exceeding and deleterious inflammatory responses, which drive IAV disease severity | Zhang et al. (2020) |
| **RSV** | RSV induces RIPK3-MLKL-dependent necroptosis of macrophages by activating TLR4/TLR3 and pyroptosis through activating TLR2 and triggering ROS generation | Bedient et al. (2020) |
| **ALI/ARDS** | Low expression of ciap2 caused RIPK1/3-dependent necroptosis of airway epithelial cells, leading to ALI/ARDS and death | Qin et al. (2019) |
| Influenza A H7N9 virus | RIPK3/MLKL-independent necroptosis is obviously activated, while lung edema and inflammation is reduced by Nec-1 | Pan et al. (2016b) |
| OA-induced ALI/ARDS | Plasma RIPK3 is associated with ALI/ARDS. RIPK3 depletion reduced inflammatory mediators and ameliorated lung tissue injury | Wang et al. (2016), Shashaty et al. (2019) |
| LPS-induced ALI/ARDS | LPS induces ZBP-1 expression, which causes RIPK3/MLKL-dependent necroptosis that results in the release of DAMPs to activate the TLR9/ (Continued on following page) | Du et al. (2019) |
### TABLE 1 | (Continued) The role of necroptosis in pulmonary diseases.

| Disease | More specific | Main content about necroptosis | References |
|---------|--------------|--------------------------------|------------|
| COPD    |              | NF-κB pathway and macrophages release pro-inflammatory cytokines, leading to lung inflammation and injury | Wang et al. (2018b) |
|         |              | The expression of CXCR1/2 and p-MLKL is high, and the SP level is high while the VIP level is low. All could be reversed by repairin, a CXCR antagonist that increased the survival rate mice of mice and improved lung inflammation | Han et al. (2018), Camino et al. (2020) |
| SARS-CoV-2 | Hyperoxia exposure causes necroptosis with increased expression of RIPK1, RIPK3, and MLKL by oxidative stress, leading to inflammatory infiltration and pulmonary edema. Hyperoxia-induced miR-185-5p promotes both apoptosis and necroptosis | Li et al. (2020a), Liu et al. (2020b) |
| Asthma  | RSV          | RSV-induced necroptosis results in the release of HMGB1 and neutrophilic that contributes to RSV bronchiolitis pathogenesis inflammation. Inhibition of necroptosis attenuated the pathologies that will ameliorate asthma progression in later-life | Simpson et al. (2020) |
|         | MUC1         | TNF-a could induce necroptosis of 16HBE cells accompanied by the upregulation of MUC1, while MUC1 downregulation increase necroptosis and inhibit the effects of anti-necroptosis by Dex | Zhang et al. (2019a), Zhang et al. (2019b) |
|         | Aspergillus-induced asthma model | RIPK1-independent necroptosis take part in adhesion-induced eosinophil cytolysis, which is required p38 MAPK and NADPH oxidase activation | Radoncic-Hoesli et al. (2017) |
|         | Adhesion-induced eosinophil cytolysis particulate matter (PM) | RIPK3-MLKL necroptosis induce the release of bioactive IL-33, which can activate basophils and eosinophils, leading to exacerbating of allergic inflammation | Zhao et al. (2019) |
| COPD    | PM           | Airborne PM exposure induces oxidative stress that can trigger necroptosis, leading to PM-induced pulmonary inflammation and mucus hyperproduction | Peixoto et al. (2017), Xu et al. (2018) |
|         | Cigarette Smoke (CS) | Induces necroptosis of lung structural cells with a release of DAMPs, leading to neutrophilic airway inflammation, which is suppressed with inhibition of GRP78 | Poureils et al. (2016), Wang et al. (2018c), Wang et al. (2020c) |
|         |              | Triggers mitophagy-dependent necroptosis via PINK1 stabilization with mitophagy, in which C16-Cer could be an upstream initiator, while highC24-DHC levels might protect against CS-induced necroptosis | Mizumura et al. (2014), Mizumura et al. (2018) |
| Idiopathic Pulmonary Fibrosis | BLM-induced model | The level of RIPK3 expression is increased in lung tissue from IPF patients. ROS production by BLM triggers RIPK3-dependent necroptosis, which takes part in fibrosis development through inflammatory cell accumulation via the release of DAMPs | Lee et al. (2018) |

(Continued on following page)
The key molecules of necroptosis are RIPK1, RIPK3, and MLKL. In tumor necrosis factor receptor (TNFR) 1-mediated necroptosis, RIPK1 combines with RIPK3 to form a necrotic complex, mediating the oligomerization of MLKL that is transported to the cell membrane, resulting in cell expansion and cell death (Shi et al., 2020). Early necroptosis was considered the alternative form of apoptosis; however increasing evidence has shown that necroptosis itself is associated with many clinical diseases. Numerous studies on diseases such as cardiovascular (Zhang et al., 2016; Li et al., 2019a; Sun T. et al., 2019), central nervous system (Yuan et al., 2019), digestive (Wang R. et al., 2020), genetic diseases (Vitner et al., 2014; Morgan et al., 2018), and various tumors (Seifert et al., 2016; Strilic et al., 2016; Seehawer et al., 2018) have demonstrated that blocking the necrotic pathway by drug inhibition, gene knockdown, or knockdown shows satisfactory results and that promoting the occurrence of necroptosis in tumors can facilitate tumor inhibition (Zhao et al., 2015; Newton et al., 2016a).

Recently, necroptosis has been found to be involved in the occurrence and development of lung diseases such as lung infections, acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and lung cancer (Table 1). However, several questions remain to be addressed.

### THE MECHANISM OF NECROPTOSIS AND ITS RELATIONSHIP WITH APOPTOSIS

The necroptosis pathway is initiated by activating Z-nucleic acid binding protein 1 (ZBPI, also known as DAI or DLM-1) (Zhang et al., 2020) or numerous ligand-dependent receptors, including tumor necrosis factor receptor (TNFR), interferon receptors (IFNRs) and Toll-like receptors (TLRs) (Choi et al., 2019). Even the necroptosis pathway can be independent of the death receptor signal when ion imbalance due to pore-forming toxin (PFT)-mediated membrane permeability is activated (Hakansson and Bergenfelz, 2017). The most typical one is the signaling pathway induced by TNFR1 (Vanden Berghe et al., 2014; Fuchs and Bergenfelz, 2017). The most typical one is the signaling pathway induced by TNFR1 (Vanden Berghe et al., 2014; Fuchs and Bergenfelz, 2017). Both RIPK1 and RIPK3 have RHIM at the C-terminal. TNFR1 activation leads to the recruitment of RIPK1 and other adapter proteins (Figure 1). Subsequently, RIPK1 and RIPK3 bind through RHIM to form an amyloid signaling complex called the necrosome (Pasparakis and Vandenabeele, 2015). RIPK3, which has a phosphorylation on Ser232 in the necrosome, recruits and phosphorylates the executioner MLKL. The phosphorylated MLKL undergoes conformational changes and disengagements from RIPK3; then, the MLKL oligomer is transferred to the cell membrane, leading to cell expansion and rupture (Wang H. et al., 2014; Garnish et al., 2021). Recently, it has been found that MLKL ubiquitination is also correlated with MLKL activation and necroptosis, and MLKL ubiquitination at K219 imposes the cytotoxic potential of phosphorylated MLKL (Garcia et al., 2021). Cell rupture is followed by the release of a large number of endogenous host-derived molecules such as adenosine triphosphate, IL-33, heat-shock proteins, and high-mobility group box 1 (HMGB1) and other DAMPs, thus causing an excessive inflammatory response and aggravating surrounding tissue damage (Scaffidi et al., 2002; Iyer et al., 2009; Gong et al., 2020).

As a typical regulatory cell death program, apoptosis is primarily mediated by caspase-mediated exogenous and endogenous signaling pathways. Death receptors, including Fas/FasL and TNF-1/TNF-α, are typical molecular models in exogenous signals that lead to cell apoptosis. Binding of these receptors and ligands to the caspase-8/caspase-10 precursor protein through the intracellular adaptor protein...
Fas-associated DD protein (FADD) activates procaspase and thus initiates the caspase cascade. Then, further activation of downstream effector molecules leads to apoptosis. Caspase is the key to many apoptotic regulatory pathways (Choi et al., 2019; Schwarzer et al., 2020). Upon the ligand activation of TNFR1, RIPK1 is ubiquitinated by the cellular inhibitors of apoptosis proteins (cIAPs) and/or linear ubiquitin chain assembly complex (LUBAC), RIPK1 ubiquitination by LUBAC or cIAPs results in the recruitment of IκB kinase (IKK) complex (including IKK1, IKK2, and the nuclear factor-kappa B (NF-κB) essential modulator [NEMO]) and transforming growth factor-β-activated kinase 1 (TAK1)-binding protein (TAB) complex, leading to the activation of mitogen-activated protein kinase and NF-κB for cell survival. Cylindromatosis (CYLD) and A20 deubiquitinate RIPK1, which is released from complex I, leading to the transition from complex I to cytosolic complex II. The binding of TRADD–Fas-associated death domain protein (FADD)–caspase-8, one complex called complex IIIa, triggers RIPK1-independent apoptosis, whereas the other complex IIb (comprising RIPK1, RIPK3, FADD, and caspase-8) triggers RIPK1-dependent apoptosis. Moreover, RIPK1 can inhibit FADD–caspase-8-dependent apoptosis. Caspase-8 can be inhibited by c-FLIP as a result of heterodimerization between c-FLIPS and procaspase-8. With the reduction, blockage, or absence of cIAPs or caspase-8, the necrosome (comprising RIPK1, RIPK3, and MLKL) is formed, which is the binding of activated RIPK1 and RIPK3, leading to the activation and phosphorylation of RIPK3. RIPK3 then activates MLKL, which is transferred to the cell membrane, ultimately leading to cell expansion and rupture and RIPK1-dependent necroptosis. RIPK3 can be activated not with RIPK1 but with other RIP homotypic interaction motif (RHIM)-containing proteins such as TLRs. TLRs can induce RIPK3 activation and RIPK1-independent necroptosis through the RHIM-containing adapter TIR domain-containing adapter-inducing interferon-β (TRIF). In the nucleus of influenza virus-infected cells, Z-RNAs are produced when replicated viruses are sensed by the host Z-DNA-binding protein 1 (ZBP1), activating RIPK3 independent of RIPK1 by its RHIM domain.

FIGURE 1 | Trigger and regulation of signal transduction pathways in necroptosis and apoptosis. Necroptosis typically occurs as a consequence of the stimulation of tumor necrosis factor receptor (TNFR) 1 by TNF, leading to the formation of receptor-bound complex I such as TNFR1-associated DD (TRADD), receptor-interacting protein (RIP) kinase (RIPK) 1, TNF-associated factor 2/5 (TRAF2/TRAF5), cellular inhibitor of apoptosis proteins (cIAPs), and linear ubiquitin chain assembly complex (LUBAC). RIPK1 ubiquitination by LUBAC or cIAPs results in the recruitment of IκB kinase (IKK) complex (including IKK1, IKK2, and the nuclear factor-kappa B (NF-κB) essential modulator [NEMO]) and transforming growth factor-β-activated kinase 1 (TAK1)-binding protein (TAB) complex, leading to the activation of mitogen-activated protein kinase and NF-κB for cell survival. Cylindromatosis (CYLD) and A20 deubiquitinate RIPK1, which is released from complex I, leading to the transition from complex I to cytosolic complex II. The binding of TRADD–Fas-associated death domain protein (FADD)–caspase-8, one complex called complex IIIa, triggers RIPK1-independent apoptosis, whereas the other complex IIb (comprising RIPK1, RIPK3, FADD, and caspase-8) triggers RIPK1-dependent apoptosis. Moreover, RIPK1 can inhibit FADD–caspase-8-dependent apoptosis. Caspase-8 can be inhibited by c-FLIP as a result of heterodimerization between c-FLIPS and procaspase-8. With the reduction, blockage, or absence of cIAPs or caspase-8, the necrosome (comprising RIPK1, RIPK3, and MLKL) is formed, which is the binding of activated RIPK1 and RIPK3, leading to the activation and phosphorylation of RIPK3. RIPK3 then activates MLKL, which is transferred to the cell membrane, ultimately leading to cell expansion and rupture and RIPK1-dependent necroptosis. RIPK3 can be activated not with RIPK1 but with other RIP homotypic interaction motif (RHIM)-containing proteins such as TLRs. TLRs can induce RIPK3 activation and RIPK1-independent necroptosis through the RHIM-containing adapter TIR domain-containing adapter-inducing interferon-β (TRIF). In the nucleus of influenza virus-infected cells, Z-RNAs are produced when replicated viruses are sensed by the host Z-DNA-binding protein 1 (ZBP1), activating RIPK3 independent of RIPK1 by its RHIM domain.
excessive activation can cause severe lung injury and thus fatal infection (Li S. et al., 2020; Gonzalez-Juärbe et al., 2020).

Actually, various cell deaths likely occur simultaneously, and recent studies have discovered the coregulation and crosstalk among these seemingly different cell death complexes. Pyroptosis is an well-known inflammatory form of cell death that requires the membrane damaging gasdermin D (GSMD) cleaved and activated by caspase-1/4/5/11. Additionally, necroptosis and pyroptosis have some overlapping downstream signals, such as trigger the NLRP3 inflammasome to result in IL-1β-driven inflammation (Frank and Vince, 2019). A new concept called PANoptosis (pyroptosis, apoptosis, and necroptosis), which is a collective inflammatory cell death pathway and engaged by a multiprotein complex called the PANoptosome, has emerged (Samir et al., 2020; Zheng and Kanneganti, 2020). A study found that TNF-α and IFN-γ synergism mediated RIPK1/FADD/CASP8 axis-derived PANoptosis in murine bone marrow-derived macrophages (BMDMs) drives pathology in COVID-19 and other diseases associated with cytokine storm (Karki et al., 2021). But it is not clear why pyroptosis, apoptosis and necroptosis are tightly connected and crossregulated each other. It is reported that Caspase-8 could be the molecular switch that controls PANoptosis to prevent tissue damage during embryonic development and adulthood (Fritsch et al., 2019). Given the complexity of cell deaths, it is necessary to exclude the interference of other cell deaths, by treating with the inhibitors or specific knockout of key molecules in one cell death, when explore the others. For example, some studies exploring the mechanism of necroptosis will block apoptosis by treatment with zVAD-fmk, in order to clarify the role of necroptosis the pathogenesis of diseases more intently (Lì et al., 2019b; Kishino et al., 2019). However, there are few studies on similar combinations among other cell deaths.

**COMPLEX NETWORK AMONG RELATED MOLECULES OF NECROPTOSIS**

RIPK1, RIPK3, and MLKL are important in necroptosis signaling pathway. The mutual restriction of death molecules plays a crucial role in regulating the balance between cell death and survival, although adverse consequences can easily occur. RIPK1 is not always involved in necroptosis (Upton et al., 2019), but it may serve as a regulator with distinct mechanisms for different modes of regulation in cell death. As a kinase, the kinase activity of RIPK1 induces RIPK3 activation and necroptosis (Geng et al., 2017). Recently, growing evidences have shown that RIPK1 phosphorylation at different sites by different kinases may regulate the kinase activity (Degterev et al., 2008; Laurien et al., 2020). Autophosphorylation of RIPK1 regulates the kinase activity of RIPK1, which may aid in particular conformational changes to facilitate necroptosis and apoptosis (Wegner et al., 2017). RIPK1 autophosphorylation at S166 regulates the kinase activity, but it cannot impose conformational changes on RIPK1 to activate the downstream cell death signaling (Laurien et al., 2020). However, phosphorylation of RIPK1 by kinases, including MAPK-activated protein kinase 2 (MK2) that phosphorylates RIPK1 at Ser321/336, TAK1 that phosphorylates RIPK1 at Ser321, NF-κB kinases (IKKs) that phosphorylate RIPK1 on multiple residues, TANK binding kinase 1 (TBK1), and IkappaB kinase epsilon (IKKe), results in the inhibition of RIPK1 kinase activity and prevents TNF-mediated RIPK1-dependent cell death (Dondelinger et al., 2015; Koppe et al., 2016; Geng et al., 2017; Jaco et al., 2017; Menon et al., 2017; Lafont et al., 2018). Recent studies have suggested that ZBP1 promotes caspase-8-mediated cell death and inflammasome activation by RHIM-mediated interactions with RIPK1, which depends on the kinase activity of RIPK1 (Muendlein et al., 2021).

The kinase-independent and scaffold-like functions of RIPK1, which mediates NF-κB and MAPK activation, are essential for cell survival. In various disease models, blocking the necroptosis pathway plays a role in promoting survival. However, interestingly, RIPK1 can inhibit necroptosis and apoptosis in the early embryonic stage during development, playing a protective role during development (Dillon et al., 2014; Newton et al., 2016b; Anderton et al., 2019; Jiao et al., 2020).

In some mouse models of development, RIPK1 inhibits FADD–caspase-8-dependent apoptosis by blocking FADD recruitment by TNFR1-associated DD and preventing abnormal caspase-8 activation. Similarly, RIPK3-dependent necroptosis driven by ZBP1 can be inhibited by RIPK1, which can prevent the binding of ZBP1 containing RHIM to RIPK3 (Newton et al., 2016b). On the basis of previous studies, mice that express RIPK1 (D325A), with a mutation in the caspase-8 cleavage site Asp325, died mid-gestation; this effect is consistent with that of a lack of caspase-8 (Newton et al., 2019; Lalaoui et al., 2020). However, evidence shows that RIPK1 can be a central driver of inflammation through its scaffold function to activate the NF-κB pathway and promote inflammatory cytokine release in the early phase; the inflammatory processes is RIPK1 kinase–dependent in the late phase (Huang et al., 2021).

In contrast to RIPK1, RIPK3 is indispensable in necroptosis (He et al., 2009; Upton et al., 2019). Various molecules can bind to RIPK3 with RHIM (Dillon et al., 2014), including ZBP1 and TIR domain-containing adaptor-inducing interferon-β (TRIF), leading to RIPK1-independent necroptosis (He et al., 2011; Kaiser et al., 2013; Thapa et al., 2016; Upton et al., 2019). RIPK3 can also mediate necroptosis and apoptosis (Cook et al., 2014; Mandal et al., 2014; Newton et al., 2014). Interestingly, RIPK3 also plays an important role in being independent of necroptosis. Studies have found that in lipopolysaccharide (LPS)-induced mouse models, RIPK3 triggers the activation of nucleotide-binding domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) inflammasomes independent of necroptosis, which indirectly illustrates the richness of RIPK3 (Lawlor et al., 2015; Chen et al., 2018; He and Wang, 2018). In mouse models of West Nile virus (WNV) encephalitis, RIPK3 can enhance the expression of neuronal chemokines and coordinate the immune response in the central nervous system. The Ripk3/−/−mice showed higher mortality with defects in recruiting immune cells than the wildtype mice, while neither...
MLKL−/− nor MLKL−/−Casp8−/− mice exhibited the defects. These data identify that RIPK3 plays a role in inhibiting the pathogenesis of WNV independent of necroptosis (Daniels et al., 2017).

MLKL is associated with endosomes and assists in endosome transport and extracellular vesicle production, independent of necroptosis (Yoon et al., 2017). Cells harboring active MLKL may not be inevitably lethal. The endosomal sorting complex required for transport-III can temporarily protect cells undergoing necroptosis to express functional proteins (Gong et al., 2017). Aside from being the executioner of necroptosis, MLKL can indirectly regulate gene expression, block specific processes via affinity for selected molecules (Zhan et al., 2021), affect cancer development and metastasis (Martens et al., 2021), and promote inflammation by activating NLRP3 (Conos et al., 2017).

THE ROLE OF NECROPTOSIS IN LUNG DISEASES

Pathogen Infection

Necroptosis has a certain defensive effect in the fight against some microorganisms or toxins infection, but it can also cause excessive inflammation and aggravate tissue damage by releasing DAMPs. Whether necroptosis plays a protective or injurious role in infectious disease may depend on the kinds of pathogen, the cell type and the degree of inflammation.

In bacterial pneumonia, most studies mention that necroptosis is detrimental. The necroptosis of immune cells, including macrophages or neutrophils, leads to the expansion of inflammatory response and increases the damage of the body; it can be alleviated by inhibiting necroptosis in mouse bacterial pneumonia model. Bacterial pathogens can cause the necroptosis of lung epithelial cells through PFTs, consumption of macrophages, or non-death receptor-dependent necroptosis through ion imbalance in the mouse pneumonia model (Gonzalez-Juarbe et al., 2015; Gonzalez-Juarbe et al., 2017; Hakansson and Bergenfelz, 2017; Gonzalez-Juarbe et al., 2018). However, PFT-induced necroptosis plays a beneficial role in facilitating adaptive immune response through the release of inflammatory factors (Riegler et al., 2019). Virulent pneumococcal strains with low NF-kB activation potential were shown to induce macrophage necroptosis, resulting in higher bacterial burden and pneumonia severity (Hakansson and Bergenfelz, 2017). In Staphylococcus aureus (S. aureus) pneumonia, immune cells such as including neutrophils and macrophages are the key to immune defense, although S. aureus can inhibit host defense by inducing the necroptosis of neutrophils and lung macrophages, thereby aggravating tissue damage and even causing the occurrence of ARDS; however, it can enhance the clearance of S. aureus and reduce lung damage by inhibiting the occurrence of necroptosis (Kitur et al., 2015; Ghimire et al., 2018; Zhou et al., 2018; Du et al., 2019; Paudel et al., 2019). A regulated process against infection called neutrophil efferocytosis impairment by Klebsiella pneumoniae (KPs) through the activation of necroptosis machinery is restored with RIPK-1 inhibitor Necrostatin (Nec)-1s or RIPK3 inhibitor GSK’872, which improve the overall disease outcome in KPn-infected mice (Jondle et al., 2018).

Interestingly, necroptosis has different effects in Mycobacterium tuberculosis (Mtb) infection. In zebrafish, the excess of TNF induces Mtb-infected macrophage necroptosis through mitochondrial reactive oxygen species (ROS) production, which releases mycobacteria into the growth-permissive extracellular milieu and disseminate Mycobacterium lentiflavum infection (Roca and Ramakrishnan, 2013). In contrast, necroptosis inhibition by MLKL-deficiency or Nec-1 in humanized mice does not affect Mtb infection progression because macrophage necroptosis is ultimately restricted to mitigate disease pathogenesis (Stutz et al., 2018a). Similarly, RIPK3 does not play a fundamental role in regulating inflammatory responses or necrotic macrophage death in vivo. Because compared with wild-type mice, RIPK3-deficient mice do not indicate the benefit of reducing the bacterial burden (Stutz et al., 2018b).

In viral pneumonia, necroptosis could be a protection against and a way for infected lung cells to restrict viral replication (Pasparakis and Vandenabeele, 2015). RIPK3-dependent necroptosis is required for protection against Vaccinia virus (VV) infection in VV-infected mice, and RIPK3−/− mice exhibit severely impaired tissues, inflammation, and uncontrollable virus replication (Cho et al., 2009). RIPK3 plays an important role in sequestering viral replication and protecting the mice against influenza A virus (IAV) infection by regulating type I IFN signaling at both the transcriptional and posttranscriptional levels. Moreover, ZBP1, a sensor of RNA viruses, is the link between IAV replication and RIPK3 activation. ZBP1−/−RIPK3-deficient mice are hypersusceptible to lethal infection caused by IAV, failing to control IAV replication and succumbing to lethal respiratory infection (Nogusa et al., 2016; Thapa et al., 2016; Downey et al., 2017; Wang Y. et al., 2019). Emerging evidence shows that Z-RNAs have been generated by replicating IAV-activated ZBP1, activating MLKL in the nucleus of infected cells, and lead to nuclear membranes rupture, resulting in an “inside-out” (i.e., nucleus-to-cytoplasm) cell death. When cell death is unrestrained, MLKL-activated nuclear envelope rupture releases nuclear DAMPs, promoting the recruitment and activation of neutrophils, which then contribute to serious consequences in mice (Zhang et al., 2020). MLKL-deficient mice had reduced IAV disease severity during secondary bacterial infection (Gonzalez-Juarbe et al., 2020). Collectively, necroptosis is an effective mechanism for the clearance of some viruses from host cells. However, SARS-CoV-2 infection triggers uncontrollable apoptosis and necroptosis, leading to lung damage in SARS-CoV-2-infected hepatocyte nuclear factor-3/forhead homolog 4- (HFH4)- human angiotensin-converting enzyme 2 (hACE2) transgenic mouse model (Li S. et al., 2020). Similarly, respiratory syncytial virus (RSV) induces lytic cell death in the human monocyte cell line (THP-1) via RIPK3-MLKL mediated necroptosis and apoptosis-associated speck-like protein containing a caspase recruitment domain-(ASC-) NLRP3 inflammasome-dependent pyroptosis. The combined treatment of GSK’872 (the RIPK3 specific inhibitor) and
zVAD-fmk (the pan-caspase inhibitor) exhibits less of lytic cell deaths than a single treatment (Bedient et al., 2020). When cell death is unrestrained, injury and severe illness follow. Although accumulating evidence demonstrates that necroptosis has a defensive effect in the fight against some microorganisms or toxins infection, further investigation is needed to elucidate the importance of necroptosis in the pathogenesis of infection diseases. And the mechanism that triggers cell death to fight infection without damaging the body needs to be explored.

**ALI/ARDS**

Several predisposing factors for ALI/ARDS exist, which include infection, trauma, and systemic inflammation. As mentioned above, lung infections, including S. aureus infection and influenza, and other systemic inflammation can result in severe lung damage, even ARDS. Much evidence shows that necroptosis is an important mechanism of inflammation that leads to lung injury. Some microorganisms or proinflammatory mediators mediate the necroptosis of immune cells, including macrophages and lung epithelial cells with significantly elevated RIPK3/MLKL. Then MLKL-induced membrane ruptures with the release of DAMPs, causing an excessive inflammatory response and aggravating lung tissue damage in mice (Wang et al., 2016; Chen et al., 2018; Fan and Fan, 2018). Both inflammation and the degree of lung injury are reduced with Nec-1, which may attenuate oxidative stress (Wang et al., 2016; Lin et al., 2020). In a neonatal septic mouse induced by intraperitoneal injection of adult cecal slurry, RIPK1 inhibition by Nec-1 has been reported to play a protective role, decreasing lung injury and increasing survival (Bolognese et al., 2018).

Growing evidence has gradually revealed the regulatory factors of necroptosis in ARDS. The death of pulmonary epithelial and infected cells is the cause of death in ALI/ARDS with A/H7N9 virus infection. cIAPs play an important role in cell survival by regulating the necroptosis pathway. However, cIAP2 is significantly downregulated and RIPK3 is increased in the lung tissues of patients who die from H7N9 infection. Collectively, a study found that necroptosis is associated with severe H7N9 infection in lung tissues from patients who died from ARDS-complicated H7N9 infection, leading to ARDS and even death, which can be regulated by cIAP2 (Qin et al., 2019). HSP90 is found to be required for RIPK3 activation through the modulation of the stability of MLKL and promotion of MLKL oligomerization and plasma membrane transformation in a mouse model of severe ARDS (Yu et al., 2020).

Some noninfectious contributing factors can induce ARDS or aggravate lung damage in ARDS. RBC transfusion sensitizes mice to LPS-induced lung inflammation through the release of the danger signal HMGB1 and induces lung endothelial cell necroptosis, which sensitizes the lung to subsequent injury (Qing et al., 2014). Some studies have demonstrated that fatty acid oxidation-dependent RIPK3 mediates the pathogenesis of ALI in patients requiring ventilator support, whereas RIPK3−/− mice sustained less severe ventilator-induced lung injury than wild-type mice (Siempos et al., 2018). In rats exposed to pure oxygen to induce hyperoxic ALI, induced oxidative stress may activate necroptosis that causes lung damage, whereas necroptosis inhibition can improve lung pathology (Han et al., 2018). In ATII cells, hyperoxia and its derivative, ROS, upregulate miR-185-5p, which can regulate both necroptosis and apoptosis by suppressing FADD and caspase-8 (Carnino et al., 2020). In a pig lung model exposed to hydrogen sulfide (H2S), necroptosis is associated with H2S-induced lung injury (Liu Z. et al., 2020). Necroptosis is significantly activated in ischemia-reperfusion injury after prolonged cold ischemic time in lung transplantation of rats/mice, which may be a key event contributing to primary graft dysfunction, whereas Nec-1 leads to a significant decrease in pathologic epithelial injury (Kanou et al., 2018; Wang X. et al., 2019). Necroptosis apparently mediated through osteopontin signaling has been reported to be associated with renal allograft transplant that triggers recipient remote lung injury in rats (Zhao et al., 2015; Zhao H. et al., 2019). Similarly, in a rat model of ARDS induced by oleic acid, necroptosis was significantly activated (Pan et al., 2016a; Pan et al., 2016b). Accordingly, necroptosis contribute to excessive inflammatory damage; manipulating necroptosis could provide new therapeutic opportunities in reducing lung damage and the severity of ARDS/ALI.

**COVID-19**

COVID-19 is caused by the novel SARS-CoV-2, with its clinical manifestations ranging from no symptoms to ARDS and even death. Severe COVID-19 is characterized by the excessive production of proinflammatory cytokines and hypercoagulability as the result of an imbalance between the innate immune system and coagulation (Jose and Manuel, 2020; Moore and June, 2020; Karki et al., 2021). SARS-CoV-2 infection results in immune cell activation. This immune response can activate coagulation pathways, leading to proinflammatory cytokine overproduction, which is described as the COVID-19 cytokine storm, and multiorgan injury (Jose and Manuel, 2020). The processes of cell death, such as pyroptosis, apoptosis, and necroptosis, may be the mechanisms that link COVID-19 cytokine storm to organ damage (Karki et al., 2021). These processes require the specific combination of TNF-α and IFN-γ with signal transducers and activators of transcription 1 (STATs)/IFN-regulatory factor 1 (IRF-1) axis, which regulates the inductive nitric oxide synthase expression for NO production. Cells stimulated with TNF-α and IFN-γ show MLKL and RIPK1 phosphorylation, suggesting that necroptosis is implicated in the COVID-19 cytokine storm. The deletion of both RIPK3 and caspase-8 is found to protect against cell death, not RIPK3 deficiency only, which shows that not only necroptosis but also other processes of cell death occur in COVID-19 (Karki et al., 2021). A previous study has reported that SARS-CoV-2-induced secretion of inflammatory cytokines, including IL-1β, depend on caspase-8 activation that triggers cell apoptosis and necroptosis pathways in the lung sections of a SARS-CoV-2-infected HFF4-hACE2 transgenic mouse model. In addition, the phosphorylation of MLKL was upregulated in the plasma of Calu-3 cells with SARS-CoV-2 infection, whereas that of pMLKL was inhibited with the inhibition of RIPK3. This suggests that SARS-CoV-2 infection trigger the apoptosis and necroptosis pathways (Li S. et al., 2020). A recent study has reported that platelets
incubated with infectious viruses appeared to undergo necroptosis and apoptosis. Phospho-MLKL and caspase-3 are increased in platelets of patients with COVID-19, showing that the necroptosis and apoptosis of platelets mediate a rapid response to SARS-CoV-2 (Koupenna et al., 2021).

Moreover, RIPK1 is a key protein in tissue-specific networks; it extensively interacts with other proteins, which suggests that RIPK1 plays an important role in inflammation or tissues damage in SARS-CoV-2 infection (Feng et al., 2020). RIPK1 activation is detected in the respiratory tract epithelium of patients with SARS-CoV-2 infection, whereas no phospho-RIPK1-positive cells are noted in the healthy individuals (Feng et al., 2020). Similarly, previous studies have demonstrated that the serum levels of RIPK3 were higher in 10 patients with COVID-19 and ARDS than in six with mild diseases, suggesting that RIPK3-mediated signal is associated with ARDS development in patients with COVID-19 (Nakamura et al., 2020). Collectively, necroptosis, the form of cell death that can trigger inflammatory responses by releasing inflammatory cytokines, may play a part in the pathogenesis and severity of COVID-19. Given that pyroptosis, apoptosis, and necroptosis are tightly connected and can crossregulate each other in COVID-19, further studies are warranted to explore the mechanism of cell death in COVID-19 to facilitate the development of therapeutic strategies.

**Asthma**

Asthma, which is characterized by airway remodeling, airway hyperresponsiveness (AHR), and reversible airway obstruction, is a heterogeneous chronic inflammatory respiratory disease induced by eosinophils (Okano et al., 2015). The inflammatory response after the release of granule by either cytolysis or degranulation of eosinophils causes increased damage in the airway epithelium and drives airway remodeling, which has been associated with asthma severity (Wark and Gibson, 2003; Okano et al., 2015; Eng and DeFelice, 2016). RIPK1-independent necroptosis has been reported to be the most likely pathway leading to eosinophil cytolysis, which can be counterregulated by autophagy (Radonjic-Hoesli et al., 2017). In a mouse model of allergic inflammation, Aspergillus fumigatus extract-induced asthma in vivo shows that bioactive IL-33, a proinflammatory cytokine, released during tissue damage to activate basophils and eosinophils is directly induced by necroptosis, which is blocked by GW806742X, a murine MLKL inhibitor (Shlomovitz et al., 2019). TNF-α is a well-known important cytokine in patients with asthma, which plays a central role in the development of AHR and other features of asthma (Brightling et al., 2008). TNF-α induces necroptosis of human bronchial epithelial (16HBE) cells accompanied by the upregulation of mucin 1 (MUC1), a membrane-tethered mucin glycoprotein, whereas MUC1 downregulation increases TNF-α-induced 16HBE cell necroptosis (Zhang et al., 2019a). Similarly, dexamethasone (Dex) has antinecrotic effects on 16HBE cell, which is inhibited by the downregulation of MUC1 with the inhibition of glucocorticoid receptor-α nuclear translocation and attenuates the inhibitory effect of Dex on phosphorylated p65 (Zhang et al., 2019b). MUC1 may serve a protective role in antinecrotic effects, which should be a potential target for the development of novel therapeutics for asthma.

In a mouse model of asthma exacerbations induced by in-house dust mite for inflammation and double-stranded RNA for exacerbation, both cell death markers, MLKL phosphorylation and lactate dehydrogenase, were increased and were observed more in IFNβ−/− mice; thus, IFN-β deficiency may be a regulator of necrosis and necroptosis (Cerps et al., 2018).

RSV infection fails to induce apoptosis, but necroptosis, leading to HMGB1 release and neutrophilic inflammation that both contribute to RSV bronchiolitis pathogenesis in RSV-infected hAECs and murine pneumovirus infected mice. Treatment with Nec-1s/GW806742X in murine pneumovirus infected mice attenuates the pathologies by decreasing viral load and preventing type-2 inflammation and airway remodeling, which will ameliorate asthma progression in later life (Simpson et al., 2020). Fine particulate matter (PM) having a diameter <2.5 μm is a well-recognized risk factor for asthma. PM2.5 can enhance AHR and trachea injury by necroptosis in BALB/c mice, inducing neutrophils and IL-17 to cause inflammation (Zhao Y. et al., 2019). Overall, necroptosis has been implicated in the severity and pathological features of asthma and necroptosis inhibition may have beneficial effects on asthma.

**COPD**

COPD, a heterogeneous and complex disease, is a progressive inflammatory disease of the airways, alveoli, and microvasculature. Cigarette smoking (CS) and indoor air pollution are common risk factors for developing COPD (Rabe and Watz, 2017; Roy, 2019). Increasing evidence suggests that multiple forms of cell death such as apoptosis, necrosis, necroptosis, and autophagy have been widely implicated in COPD pathogenesis (Kaup et al., 1990; Yokohori et al., 2004; Ryter et al., 2009; POUWELS ET AL., 2016). CS exposure induces necroptosis in lung structural cells with the release of DAMPs, leading to neutrophilic airway inflammation in mice (POUWELS ET AL., 2016; WANG Y. ET AL., 2018). However, CS-induced necroptosis is significantly suppressed with the inhibition of GRP78, a member of the HSP70 family (WANG Y. ET AL., 2018). Similarly, a recent study reported that RIPK1/3 and MLKL were increased in CS-induced murine experimental COPD. pRIPK3 and pMLKL were also more increased in the lung tissues of patients with severe COPD than in those of nonsmokers or non-COPD smokers. Importantly, cellular and molecular airway inflammations were reduced in RIPK3−/− and MLKL−/− mice. MLKL−/− mice also had a suppressed airway remodeling and emphysema, but no treatment inhibited the apoptosis (pan-caspase inhibitor qVD-OPh) (LU et al., 2021). Another recent study also reported the same conclusion that CS-induced necroptosis contributes to the pathogenesis of COPD. However, Nec-1 treatment or RIPK1 silencing by siRNA did not protect against CS-induced emphysema and or suppress the lung inflammation in mice, while RIPK3 inhibitor GSK’872 had the protective effect (CHEN ET AL., 2021). Moreover, airborne PM exposure can trigger necroptosis in human bronchial epithelial (HBE) cells or mouse airways, which is involved in the
necroptosis in lung. are needed to clarify the role and mechanism of CS-induced
be an upstream initiator (Mizumura et al., 2018). Further studies
regulated lethal mitophagy and mitophagy-mediated
against CS-induced necroptosis. In conclusion, PINK1-
High lignoceroyl (C24)-dihydroceramide levels may protect
palmitoyl (C16)-ceramide (Cer), which is an important mediator.
which requires the stabilization of PINK1 with mitophagy
epithelial and endothelial cells, CS exposure triggers necroptosis,
dysfunction. Interestingly, an emerging hypothesis states that CS-
exposure has been found to cause mitophagy and mitochondrial
dysfunction. Interestingly, an emerging hypothesis states that CS-
induced mitophagy is involved in necroptosis in pulmonary
epithelial cells and murine models (Mizumura et al., 2014). A
study reported that the expression level of PTEN-induced kinase
1 (PINK1) and RIPK3 was increased in human epithelial cells
with COPD. However, CS-induced cell death, mitochondrial
dysfunction, and MLKL phosphorylation are blocked in
PINK1-knockdown cells and mitophagy inhibitor Mdivi-1-
treated Beas-2B cells (Mizumura et al., 2014). In human lung
epithelial and endothelial cells, CS exposure triggers necroptosis,
which requires the stabilization of PINK1 with mitophagy
through a mechanism involving the excessive accumulation of
palmitoyl (C16)-ceramide (Cer), which is an important mediator.
High lignoceroyl (C24)-dihydroceramide levels may protect
against CS-induced necroptosis. In conclusion, PINK1-
regulated lethal mitophagy and mitophagy-mediated
necroptosis both contribute to COPD, in which C16-Cer could
be an upstream initiator (Mizumura et al., 2018). Further studies
are needed to clarify the role and mechanism of CS-induced
necroptosis in lung.

Idiopathic Pulmonary Fibrosis
Particulate inhalation, genetic susceptibility, and CS play a role in IPF
pathogenesis and progression. IPF is characterized by type 1/2 alveolar
epithelial cell (AEC1/AEC2) injury and failure to repair, with the
consequential activation of fibroblast/myofibroblasts that destroy
normal alveolar architecture (Richeldi et al., 2017). Necroptosis
is believed to be implicated in IPF development. In the lung tissue
of patients with IPF, the level of RIPK3 expression is increased, indicating
the involvement of necroptosis in IPF. RIPK3, HMGB1, and IL-1β
levels have been reported to increase in bleomycin-induced IPF model;
however, these levels were reduced in RIPK3-knockout mice and by
Nec-1 that exhibits an inhibitory effect on inflammation and fibrosis
(Lee et al., 2018). Mutation in SFTPA1 resulted in IPF in a
consanguineous Japanese family, and SFTPA1 knock-in (Sftp1a1-
KI) mice spontaneously developed pulmonary fibrosis with
increased necroptosis derived by c-Jun N-terminal kinase (JNK)-
mediated upregulation of RIPK3 in AEC2s. JNK inhibition ameliorated
pulmonary fibrosis in Sftp1a1-KI mice, but it was blocked with RIPK3 overexpression (Takezaki et al., 2019).

Interestingly, IPF and COPD have a lot in common in terms of
pathogenesis, including their relationship with smoking, lung
aging biopathological processes (Duckworth et al., 2021; Schuliga
et al., 2021) and necroptosis-involved pathological mechanisms.
A study reported that CS aggravates bleomycin-induced
pulmonary fibrosis via TGF-β1 signaling, but necroptosis was not
mentioned (Zhou et al., 2019). It will be interesting to explore
the function of necroptosis in CS-related pulmonary fibrosis and
determine if CS-induced necroptosis leads to IPF or COPD.

Pulmonary Arterial Hypertension
PAH is a progressive cardiopulmonary disease characterized by perivascular infiltration by inflammatory cells, adverse vascular
remodeling, vascular fibrosis, and stiffening. Some preclinical
studies have shown that inflammation plays a pathogenic role in
PAH development and advanced vascular remodeling may be reversed by approaches addressing specific inflammatory and
immune processes (Rabinovitch et al., 2014). Evidence showing
that necroptosis is implicated in PAH is limited. HMGB1, one of
the DAMPs, plays a crucial role in the development of PAH and
manifestation of sex difference in PAH severity. Males are prone
to show a more progressive and severe PAH development with a
higher level of circulating HMGB1, which may mediate
downstream signaling through TLR4 activation. Necroptosis
and necrosis are the primary sources of circulating HMGB1 in
male rats, whereas only the attenuation of necrosis prevents TLR4
activation and blunts the sex differences in PAH severity.
Collectively, necroptosis and necrosis play a potential role in
HMGB1 release, TLR4 activation, and sex difference manifestation in PAH severity (Zemskova et al., 2020).
Similarly, in a rat model of monocrotaline-induced PAH,
bioinformatics analysis revealed that RIPK3-mediated
necroptosis is involved in the generation of DAMPs that are
associated with the activation of TLR and NOD-like receptor
pathways (Xiao et al., 2020).

Lung Cancer
Aptosis plays a well-recognized role in defenses against
tumors, whereas the evasion of and resistance to apoptosis is
often responsible for both tumorigenesis and chemotherapeutic drug resistance (Hanahan and
Weinberg, 2011; Gong et al., 2019). The role of
necroptosis in tumors is complicated, involving
tumorigenesis and malignant progression, promoting
tumor metastasis and drug resistance. Evidence shows that
tumors induce endothelial cell necroptosis, leading to
extravasation and metastasis via the amyloid precursor
protein and its receptor, death receptor 6, which is
expressed on endothelial cells as a primary mediator.
These effects can be blocked with Nec-1 or RIPK3 deletion
(Strilic et al., 2016). Similarly, TAK1 plays an inhibitory role in
endothelial necroptosis and metastasis. TAK1 deficiency is
more likely to cause RIPK3-dependent necroptosis of human/
murine endothelial cells by upregulating RIPK3 expression
and form metastases by the endothelium (Yang et al., 2019).
However, necroptosis may trigger and amplify antitumor
immunity in cancer therapy by eliciting strong adaptive
immune responses to defend against tumor progression
(Su et al., 2016; Gong et al., 2019). Several studies have
reported that various cancer cells can undergo necroptosis
due to necroptosis inducers and chemotherapeutic agents.
(Table 2). An interesting study has also identified that many cancer cells have intrinsic or acquired defects in the mechanism of necroptosis (Su et al., 2016). RIPK3, the key regulatory factor of necroptosis, shows the potential for predicting response after treatment. In one situation, a high level of RIPK3 was associated with improved local control and progression-free survival in patients with non-small cell lung cancer (NSCLC) after hypofractionated radiation therapy (Wang HH, et al., 2018). In another situation, low RIPK3 showed worse disease-free survival (DFS) after curative resection in patients with NSCLC (Park et al., 2020). Similarly, patients with NSCLC who have lower RIPK3 expression have worse chemotherapy responses (Wang Q. et al., 2020). Thus, RIPK3-mediated necroptosis pathway may be suppressed in lung cancer cells and lose its antitumor function. However, a study with 404 patients of NSCLC found that a higher RIPK3 expression is associated with shorter overall survival and a tendency of shorter DFS, which might be caused by the resistance to radiotherapy or excessive necroptosis-mediated damage (Kim et al., 2020). Nevertheless, necroptosis-based antitumor may be a promising therapeutic strategy worthy of further investigation. A better understanding of the role of necroptosis in lung cancer is expected to exploit necroptosis for lung cancer therapies. Certainly, concerns such as how to specifically

**Table 2** | Substances that have an inhibitory effect on tumors by mediating necroptosis.

| Classification          | Name                         | Source                                                                 | Mechanism                                                                 |
|-------------------------|------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Natural compounds or    | 2-methoxy-6-acetyl-7-methyljuglone (MAM) (Sun et al., 2016; Sun et al., 2019b) | A naphthoquinone isolated from Polygonum cuspidatum | Induce NO-dependent necroptosis or apoptosis mediated by H2O2-dependent JNK activation in cancer cells |
| extracts                |                              |                                                                        |                                                                           |
|                         | Tanshinol A (TSA) (Liu et al., 2020a) | A tanshinone that isolated from the roots of Danshen | Trigger MLKL-dependent necroptosis that independent RIPK1/RIPK3 and calcium. ROS might promote the upstream of MLKL. |
|                         | sea hare hydrolysates (SHH) (Nyiramana et al., 2020) | A hydrolysate from Sea Hare | SHH has effects against lung cancer by activating M1 (as anti-tumor effects), reducing M2, inhibiting growth and migration, and being cytotoxicity. Pyroptosis/necroptosis take part in SHH-induced antitumor effects under STAT3 inhibition |
|                         | Shikonin (Km et al., 2017) | Purified from lithospermum erythrorhizon | Induce necroptosis and autophagy in NSCLC cells. Necroptosis is enhanced by inhibition of shikonin-induced autophagy |
| Substances in tumor cells | Citronellol (Yu et al., 2019) | A monoterpene having the molecular formula of C10H20O | Induce necroptosis of NCI-H1299 cells by TNF-α pathway and ROS accumulation |
|                         | Betanodavirus B2 protein (Chiu et al., 2017) | Encoded by a sub-genomic RNA3 in betanodaviruses replication | Trigger apoptosis required P53 activation and RIPK3-dependent necroptosis by ROS |
|                         | Sirtuin (SIRT3) (Tang et al., 2020) | A member of the Sirtuin family of nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases | Keep mutant p53 stable by controlling proteasomal degradation triggered by ubiquitination and has anti-tumor effects by inducing apoptosis and necroptosis |
|                         | Kras-derived exosomes (Petanidis et al., 2020) | A exosomes | Treatment with carboplatin and inhibition of Kras secreted exosomes induce TNFa-mediated RIPK3-dependent necroptosis and reduce miR-146/miR-210 levels that have the effects of immunosuppressive. Reduction in miR-146/miR-210 levels accompanied by a reduction in immunosuppressive |
|                         | PITPa (Jing et al., 2018) | A family member of PITPs | Promote cisplatin-induced MLKL-dependent necroptosis by increasing oligomerization and plasma membrane translocation |
| Synthetic compound      | 3-bromomethylbenzofuran-2-carboxylic acid ethyl ester (MCC1019) (Abdelifatah et al., 2019) | Drug-like compounds | Suppress Akt signaling pathway activation. Prolong mitotic arrest and induced apoptosis and necroptosis |
|                         | 2-amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol; Fingolimod, Novartis (FTY720) (Saddoughi et al., 2013) | A synthetic sphingosine analogue of myriocin | Binds I2PP2A/SET then activate PP2A tumor suppressor signaling, and induce RIPK1-mediated necroptosis |
|                         | LGH00168 (Ma et al., 2016) | Drug-like compounds, C/EBP homologous protein (CHOP) activator | A CHOP activator that induces necroptosis by ROS-mediated ER stress, CHOP activation, and NF-κB inhibition |
|                         | ethyl 6-(5-phenylsulfonamido)pyridin-3-yl) imidazo[1,2,4]triazole-3-carboxylate (H-S173) (Park et al., 2019) | The imidazopyridine derivative | Induce necroptosis by enhancing RIPK3 expression and activating the RIPK3/MLKL signaling pathway in lung cancer cells |
|                         | Pk68 (Hou et al., 2019) | A potent and selective type II RIPK1 inhibitor | Prophylactic use of Pk68 has an inhibitory effect on tumor metastasis |
induce the necroptosis of cancer cells, whether necroptosis-based antitumor has a deleterious role, and how to overcome necroptosis resistance in cancer cells still exist (Su et al., 2016; Gong et al., 2019).

OPPORTUNITIES FOR THERAPY

Collectively, necroptosis is closely related to multiple human pathologies and inappropriate necroptosis causes excessive immune or inflammatory responses and tissue damage, leading to condition deterioration. Clearly, interrupting the necroptosis pathway by inhibitors will exert strong beneficial effects. Few trials show that inhibitors of necroptosis-related molecules were being developed for the treatment of psoriasis, rheumatoid arthritis, ulcerative colitis, and other inflammatory diseases or cancer (Fang et al., 2021).

GSK2982772 is a RIPK1 inhibitor. The first-in-human study showed that single and repeat doses of GSK2982772 were generally safe and well-tolerated in healthy adult volunteers, which support progression into Phase II clinical trials (Weisel et al., 2017; Tompson et al., 2021). The phase 2a clinical trials showed a certain therapeutic effect on active plaque psoriasis, and other phase 2a clinical trials in moderate to severe psoriasis are currently underway (Weisel et al., 2020). However, the phase 2a clinical trials showed GSK2982772 have no effects in severe rheumatoid arthritis and active ulcerative colitis (Weisel et al., 2021a; Weisel et al., 2021b). Different effects may be related to the type of disease or due to the small number of patients included in the trials.

DNL104, a selective centrally penetrant RIPK1 inhibitor, is generally safe and well-tolerated in the clinical development for Alzheimer’s disease and amyotrophic lateral sclerosis in a randomized phase I ascending dose study in healthy volunteers (Grievink et al., 2020). Interestingly, some US Food and Drug Administration-approved anticancer drugs, including ponatinib and pazopanib, can inhibit RIPK1; these drugs would be better prospects in further clinical studies (Fauster et al., 2015). However, there is only limited evidence regarding the inhibitors of necroptosis-related molecules for the treatment of pulmonary diseases. More inhibitors that are suitable for advancement into the clinic have yet to be described.

CONCLUSION

Necroptosis, as a major pathway of RCD, is important in the embryonic and postnatal development and causes an innate immune response to protect the body, especially in cases of viral infections and tumors. Increasing evidences shows that necroptosis is a possible target for the treatment of pulmonary diseases in the future.

However, many questions are yet to be addressed. The establishment of specific, sensitive, and reliable molecular markers of necroptosis is important because necroptosis-relevant proteins have a variety of functions, including RCD-unrelated functions. The correlation among various RCDs, extent to which necroptosis and apoptosis pathways are different, and connection mechanism between two cell deaths remain unclear. Moreover, studying how necroptosis connects to other biological processes is conducive to the development of targeted drugs for necroptosis without overreaction or sequela. Most importantly, more clinical trials are needed to confirm the roles of necroptosis inhibitors or other necroptosis-targeting drugs. In addition, targeting immune enhancement and tumor suppression may be the future direction of treatment. The effects and side effects of necroptosis-targeting drugs should be studied further in the future.

AUTHOR CONTRIBUTIONS

LW, LZ, HZ, and HL conceived and designed research; LW and LZ drafted manuscript; YZ, LL, and WJ prepared figures and tables; LW, LZ, HZ, and HL edited and revised the manuscript; LW, LZ, YZ, LL, WJ, HZ, and HL approved the final version of the manuscript.

FUNDING

This study was supported by the National Key Research and Development Program of China (Project 523 No. 2016YFC1304203) and the National Natural Science Foundation of China (No. 81770088).

REFERENCES

Abdelfatah, S., Berg, A., Huang, Q., Yang, L. J., Hamdoun, S., Klinger, A., et al. (2019). MCC1019, a Selective Inhibitor of the Polo-box Domain of Polo-like Kinase 1 as Novel, Potent Anticancer Candidate. Acta Pharm. Sin B 9 (5), 1021–1034. doi:10.1016/j.apsb.2019.02.001

Anderton, H., Bandala-Sanchez, E., Simpson, D. S., Rickard, J. A., Ng, A. P., Di Rago, L., et al. (2019). RIPK1 Prevents TRADD-Driven, but TNFR1 Independent, Apoptosis during Development. Cell Death Differ 26 (5), 877–889. doi:10.1038/s41418-018-0166-8

Bedient, L., Pokhariel, S. M., Chio, K. R., Mohanty, I., Beach, S. S., Miura, T. A., et al. (2020). Lytic Cell Death Mechanisms in Human Respiratory Syncytial Virus-Infected Macrophages: Roles of Pyroptosis and Necroptosis. Viruses 12 (9), 932. doi:10.3390/v12090932

Bolognese, A. C., Yang, W.-L., Hansen, I. W., Denning, N.-L., Nicastro, J. M., Coppa, G. F., et al. (2018). Inhibition of Necroptosis Attenuates Lung Injury and Improves Survival in Neonatal Sepsis. Surgery 164, 110–116. doi:10.1016/j.surg.2018.02.017

Brightling, C., Berry, M., and Amrani, Y. (2008). Targeting TNF-Alpha: a Novel Therapeutic Approach for Asthma. J. Allergy Clin. Immunol. Therapeutic Approach for Asthma. 121 (1), 5–2. doi:10.1016/j.jaci.2007.10.028

Butler, R. E., Krishnan, N., Garcia-Jimenez, W., Francis, R., Martyn, A., Mendum, T., et al. (2017). Susceptibility of Mycobacterium Tuberculosis-Infected Host Cells to Phospho-MLKL Driven Necroptosis Is Dependent on Cell Type and Presence of TNFa. Virulence 8 (8), 1820–1832. doi:10.1080/21505594.2017.1377881

Carnino, J. M., Lee, H., He, X., Groot, M., and Jin, Y. (2020). Extracellular Vesicle-Cargo miR-185-5p Reflects Type II Alveolar Cell Death after Oxidative Stress. Cell Death Discov 6, 82. doi:10.1038/s41420-020-00317-8
Wang, X., Li, Y., Shi, C., et al. (2020b). Direct Activation of Wang, Y., Wang, X. K., Wu, P. P., Wang, Y., Ren, L. Y., and Xu, A. H. (2020c). Necroptosis Wang, Q., Wang, P., Zhang, L., Tessema, M., Bai, L., Xu, X., et al. (2020a). Wang et al. Necroptosis in Pulmonary Diseases Xu, F., Luo, M., He, L., Cao, Y., Li, W., Ying, S., et al. (2018). Necroptosis Yokohori, N., Aoshiba, K., and Nagai, A. (2004). Increased Levels of Cell Death and Xiao, G., Zhuang, W., Wang, T., Lian, G., Luo, L., Ye, C., et al. (2020). Weisel, K., Berger, S., Thorn, K., Taylor, P. C., Peterfy, C., Siddall, H., et al. (2021a). Pharmacodynamics of RIPK1 Inhibitor GSK2982772 in Healthy Volunteers. doi:10.1136/bmjgast-2021-000680

Zhang, T., Yin, C., Boyd, D. F., Quarto, G., Ingram, J. P., Shubina, M., et al. (2020). Influenza Virus Z-RNAs Induce ZBP1-Mediated Necroptosis. Cell 180 (6), 1115–1125. doi:10.1016/j.cell.2020.02.050

Zhao, H., Chen, Q., Huang, H., Suen, K. C., Alam, A., Cui, J., et al. (2019a). Osteopontin Mediates Necroptosis in Lung Injury after Transplantation of Ischaemic Renal Allografts in Rats. Br. J. Anaesth. 123 (4), 519–530. doi:10.1016/j.bja.2019.05.041

Zhao, H., Ding, J., Lemaire, A., Kosmpa, F. S., Sun, J. J., Fung, A., et al. (2015). Inducing Necroptosis in BALB/c Mice. Toxicol. Pathol. 43 (3), 680–690. doi:10.1177/0192623315616467

Zhou, Y., Niu, C., Ma, B., Xue, X., Li, Z., Chen, Z., et al. (2018). Inhibiting PSM Mediates Necroptosis, Also Regulates Endosomal Trafﬁcking and Extracellular Vesicle Generation. Cell Death Differ. 25 (1), 1–11. doi:10.1038/cdd.2017.146

Zhu, Y., Liu, C., Ma, B., Xue, X., Li, Z., Chen, Z., et al. (2018). Inhibiting PSMA-Induced Neutrophil Necroptosis Protects Mice with MBSA Pneumonia by Blocking the Agr System. Cell Death Dis. 9 (3), 362. doi:10.1038/s41419-018-0398-z

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Zhou, Zhou, Liu, Li, Zhang and Liu. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.